Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Shipley

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Clinical Lung Cancer|June 14, 2011
A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancerDavid R Spigel, F Anthony Greco, Howard A Burris, et al.
British Journal of Pharmacology|May 2, 2003
Effects of different beta adrenoceptor ligands in mice with permanent occlusion of the left anterior descending coronary arteryZsuzsanna Callaerts-Vegh, Kenda L J Evans, Gregory L Shipley, et al.
Gynecologic Oncology|April 1, 2014
CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesityQian Zhang, Rosemarie Schmandt, Joseph Celestino, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research ConsortiumDavid R Spigel, John D Hainsworth, Dianna L Shipley, et al.
Clinical Colorectal Cancer|August 16, 2011
Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancerDavid R Spigel, Johanna C Bendell, Michael McCleod, et al.
Clinical Chemistry|February 28, 2009
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experimentsStephen A Bustin, Vladimir Benes, Jeremy A Garson, et al.
Clinical Chemistry|March 23, 2011
Primer sequence disclosure: a clarification of the MIQE guidelinesStephen A Bustin, Vladimir Benes, Jeremy A Garson, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)David R Spigel, Mark S Rubin, Victor G Gian, et al.
Cardiology|July 30, 2002
Downregulation of metabolic gene expression in failing human heart before and after mechanical unloadingPeter Razeghi, Martin E Young, Jun Ying, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 9, 2011
A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancerDavid R Spigel, John D Hainsworth, Dianna L Shipley, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Clinical Lung Cancer|June 14, 2011
A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancerDavid R Spigel, F Anthony Greco, Howard A Burris, et al.
British Journal of Pharmacology|May 2, 2003
Effects of different beta adrenoceptor ligands in mice with permanent occlusion of the left anterior descending coronary arteryZsuzsanna Callaerts-Vegh, Kenda L J Evans, Gregory L Shipley, et al.
Gynecologic Oncology|April 1, 2014
CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesityQian Zhang, Rosemarie Schmandt, Joseph Celestino, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research ConsortiumDavid R Spigel, John D Hainsworth, Dianna L Shipley, et al.
Clinical Colorectal Cancer|August 16, 2011
Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancerDavid R Spigel, Johanna C Bendell, Michael McCleod, et al.
Clinical Chemistry|February 28, 2009
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experimentsStephen A Bustin, Vladimir Benes, Jeremy A Garson, et al.
Clinical Chemistry|March 23, 2011
Primer sequence disclosure: a clarification of the MIQE guidelinesStephen A Bustin, Vladimir Benes, Jeremy A Garson, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)David R Spigel, Mark S Rubin, Victor G Gian, et al.
Cardiology|July 30, 2002
Downregulation of metabolic gene expression in failing human heart before and after mechanical unloadingPeter Razeghi, Martin E Young, Jun Ying, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 9, 2011
A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancerDavid R Spigel, John D Hainsworth, Dianna L Shipley, et al.
Pageof 11